Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Peking promotes the large-scale deployment of 10,000 embodied Siasun Robot&Automation, with policy support accelerating industry development.

The "Peking Embodied Asia Vets Technology Innovation and Industry Cultivation Action Plan (2025-2027)" was officially released in Peking. The "Action Plan" states that by 2027, efforts will aim to implement the large-scale deployment of ten thousand embodied Siasun Robot&Automation units and cultivate a trillion-level industrial cluster.

cls.cnMar 2 18:58 ET

JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement

① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.

cls.cnFeb 26 09:00 ET

The final ruling has changed! Innovative Medical Management has revised its 2024 performance forecast, with the company accumulating losses of nearly 1.8 billion over six years | Interpretations

① Only a month after the performance forecast for 2024 was disclosed, Innovative Medical Management has revised its performance forecast, with net losses expanding to 0.1 billion yuan - -85 million yuan; ② Innovative Medical Management had made relevant risk warnings in its performance forecast, and the dispute case between Qianhai Excellence and Jianhua Hospital has been heard but not yet ruled; ③ Since 2019, Innovative Medical Management has reported losses for six consecutive years, with a cumulative loss amounting to nearly 1.8 billion yuan.

cls.cnFeb 25 09:10 ET

It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.

① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.

cls.cnFeb 20 18:46 ET

Shanghai Haohai Biological Technology's net profit growth is weak in 2024, and the Industry is facing a period of performance pain.

① In terms of quarterly performance, Shanghai Haohai Biological Technology achieved a net income of 79.27 million yuan in the fourth quarter, a year-on-year decrease of 11.26% and a quarter-on-quarter decrease of 24.93%. ② The "Shanghai Haohai Biological Technology International Pharmaceutical Research and Development and Industrialization Project" has partially been put into use, and the production capacity for businesses like hyaluronic acid will gradually be released.

cls.cnFeb 19 08:00 ET